Developmental history of the extent of lymph node dissection in pancreatic cancer surgery

Gou ShanMiao; Wu HeShui

doi:10.3969/j.issn.1001-5256.2017.01.012

Issue 1

Jan. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(1): 57-60

PDF( 1526 KB)

Developmental history of the extent of lymph node dissection in pancreatic cancer surgery

DOI: 10.3969/j.issn.1001-5256.2017.01.012

Department of Pancreatic Surgery,Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Received Date: 2016-09-19
Published Date: 2017-01-20

Abstract

Abstract

Pancreatic cancer is one of the digestive malignant tumors with the worst prognosis and has an overall 5- year survival rate as low as 5%. Even though radical resection is performed,the 5- year survival rate is only about 20%. Recurrence and metastasis are the most important influencing factors for the postoperative survival of patients with pancreatic cancer. Lymph node metastasis is an important feature of pancreatic cancer,and the extent of lymph node dissection has always been a hot topic in radical surgery for pancreatic cancer. This article summarizes the history and current status of the extent of lymph node dissection in pancreatic cancer and points out that standardized lymph node dissection is a key factor for improving patients' prognosis after pancreatic cancer surgery.
- pancreatic neoplasms,
- lymph node excision,
- surgical procedures

FullText(HTML)

References(24)

References

[1]SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.

[2]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.

[3]ANDRIULLI A,FESTA V,BOTTERI E,et al.Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer:a meta-analysis of prospective studies[J].Ann Surg Oncol,2012,19(5):1644-1662.

[4]DAVIS JL,PANDALAI PK,RIPLEY RT,et al.Expanding surgical treatment of pancreatic cancer:the role of regional chemotherapy[J].Pancreas,2012,41(5):678-684.

[5]DRAGOVICH T.Is there a case for personalized therapy of pancreatic cancer?[J].Clin Adv Hematol Oncol,2012,10(5):344-345.

[6]PORUK KE,FIRPO MA,ADLER DG,et al.Screening for pancreatic cancer:why,how,and who?[J].Ann Surg,2013,257(1):17-26.

[7]HARTWIG W,VOLLMER CM,FINGERHUT A,et al.Extended pancreatectomy in pancreatic ductal adenocarcinoma:definition and consensus of the International Study Group for Pancreatic Surgery(ISGPS)[J].Surgery,2014,156(1):1-14.

[8]Japan Pancreas Society.General rules for cancer of the pancreas[M].3rd ed.Tokyo:Kanehara Shuppan,1986.

[9]ISHIKAWA O,OHHIGASHI H,SASAKI Y,et al.Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head[J].Ann Surg,1988,208(2):215-220.

[10]MANABE T,OHSHIO G,BABA N,et al.Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas[J].Cancer,1989,64(5):1132-1137.

[11]HENNE-BRUNS D,VOGEL I,LTTGES J,et al.Ductal adenocarcinoma of the pancreas head:survival after regional versus extended lymphadenectomy[J].Hepatogastroenterology,1998,45(21):855-866.

[12]MUKAIYA M,HIRATA K,SATOH T,et al.Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas:retrospective multi-institutional analysis in Japan[J].World J Surg,1998,22(3):248-252.

[13]YEO CJ,BASTIDAS JA,SCHMIEG RE Jr,et al.Pancreatic structure and glucose tolerance in a longitudinal study of experimental pancreatitis-induced diabetes[J].Ann Surg,1989,210(2):150-158.

[14]YEO CJ,CAMERON JL,LILLEMOE KD,et al.Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma,part 2:randomized controlled trial evaluating survival,morbidity,and mortality[J].Ann Surg,2002,236(3):355-366.

[15]PEDRAZZOLI S,DICARLO V,DIONIGI R,et al.Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas:a multicenter,prospective,randomized study.Lymphadenectomy Study Group[J].Ann Surg,1998,228(4):508-517.

[16]POPIELA T,KEDRA B,SIERZEGA M,et al.Does extended lymphadenectomy improve survival of pancreatic cancer patients?[J].Acta Chir Belg,2002,102(2):78-82.

[17]FARNELL MB,PEARSON RK,SARR MG,et al.A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma[J].Surgery,2005,138(4):618-628.

[18]Japan Pancreas Society.Classification of pancreatic carcinoma[M].2nd English ed.Tokyo:Kanehara Shuppan,2003.

[19]TEMPERO MA,MALAFA MP,BEHRMAN SW,et al.Pancreatic adenocarcinoma,version 2.2014:featured updates to the NCCN guidelines[J].J Natl Compr Canc Netw,2014,12(8):1083-1093.

[20]TOL JA,GOUMA DJ,BASSI C,et al.Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma:a consensus statement by the International Study Group on Pancreatic Surgery(ISGPS)[J].Surgery,2014,156(3):591-600.

[21]CONNOR S,BOSONNET L,GHANEH P,et al.Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status[J].Br J Surg,2004,91(12):1592-1599.

[22] Group of Pancreas Surgery,Chinese Society of Surgery,Chinese Medical Association.Guidelines for the management of pancreatic cancer(2014)[J].J Clin Hepatol,2014,30(12):1240-1245.(in Chinese)中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南(2014)[J].临床肝胆病杂志,2014,30(12):1240-1245.

[23]PAIELLA S,SANDINI M,GIANOTTI L,et al.The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer:a systematic review and meta-analysis[J].Eur J Surg Oncol,2016,42(5):616-624.

[24]KAWABATA Y,TANAKA T,ISHIKAWA N,et al.Modified total meso-pancreatoduodenum excision with pancreaticoduodenectomy as a mesopancreatic plane surgery in borderline resectable pancreatic cancer[J].Eur J Surg Oncol,2016,42(5):698-705.

Relative Articles

[1]	Ting MAO, Mingyi XU, Jiayi WANG. Characteristics of T cells in the liver tissues of mice with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2025, 41(3): 461-468. doi: 10.12449/JCH250311
[2]	Shuang LI, Zherui LIU, Qi ZHAO, Yinying LU. Clinical research advances in chimeric antigen receptor T-cell therapy for primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(5): 1019-1029. doi: 10.3969/j.issn.1001-5256.2023.05.004
[3]	Xue WEN, Yujing HE, Qianqian YUAN, Chuyi LI, Lixia LU, Xiaohui YU, Jiucong ZHANG. Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance[J]. Journal of Clinical Hepatology, 2023, 39(4): 810-817. doi: 10.3969/j.issn.1001-5256.2023.04.011
[4]	Ziyi LI, Wanjie ZHANG, Fuchun WANG, Xiaorong MAO, Junfeng LI. Role of T lymphocytes in primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2926-2931. doi: 10.3969/j.issn.1001-5256.2023.12.026
[5]	Huijuan FAN, Chun SONG. Expression of peripheral CD100 and its regulation to T lymphocytes function in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(1): 128-136. doi: 10.3969/j.issn.1001-5256.2023.01.019
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Xiaofei YANG, Linxu WANG, Changxing HUANG, Jie DONG, Haifeng HU, Zhanhu BI, Jianqi LIAN, Ye ZHANG. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8⁺ T cells of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2021, 37(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2021.05.017
[8]	Wang HaoLiang, Deng GuoHong. Functional status of hepatitis B virus-specific T cells in patients with chronic hepatitis B virus infection:Exhausted or silenced?[J]. Journal of Clinical Hepatology, 2020, 36(5): 980-982. doi: 10.3969/j.issn.1001-5256.2020.05.005
[9]	Gao MengDan, Tan Ling, Sun JianPing, Li Kang, Li Ang, Lou JinLi, Zhang YongHong, Zhao Yan. Expression and significance of T-cell immunoglobulin and mucin domain-containing molecule 3 in peripheral blood CD3+CD56+ natural killer T cells in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(9): 2006-2010. doi: 10.3969/j.issn.1001-5256.2019.09.024
[10]	Gao Yi, Liang ZhiJun, Fu Jian. Influence of interleukin-35 on peripheral CD8+ T cell function in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(9): 2011-2016. doi: 10.3969/j.issn.1001-5256.2019.09.025
[11]	Ge KuanXue, Gao WeiHua, Xiang XiaoXing. Association of regulatory T cells, T helper 17 cells, and change in their balance with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1573-1576. doi: 10.3969/j.issn.1001-5256.2018.07.045
[12]	Xiong KeGong, Ke KunYu, Kong JinFeng, Liu LiJuan, Chen LiFang, Lin XiaoQin. Expression of programmed death-ligand 1 on peripheral blood T cells and its correlation with liver inflammation grade in patients with type 1 autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1248-1252. doi: 10.3969/j.issn.1001-5256.2018.06.023
[13]	Zhang Ke, Yang Fan, Sun YanLing, Liu ZhenWen, Wang FuSheng, Shi Ming. Characteristics and clinical significance of peripheral follicular cytotoxic T cells in patients experiencing acute rejection after liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(7): 1336-1339. doi: 10.3969/j.issn.1001-5256.2017.07.027
[14]	Yin SiHan, Liu Peng, Zhang Tao, Sun KeWei. Analysis of TCM deficiency and excess attributes in patients with HBV- related acute- on- chronic liver failure based on phenotype of dendritic cells and function of T lymphocytes[J]. Journal of Clinical Hepatology, 2016, 32(4): 663-668. doi: 10.3969/j.issn.1001-5256.2016.04.010
[15]	Hou YuLi, Zhang YongHong, Zhao Yan. Immunological characteristics of tumor antigen specific T cells and their possible mechanisms in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(6): 1220-1224. doi: 10.3969/j.issn.1001-5256.2016.06.048
[16]	Cao Hui, Zhang Yang, Tan ShanZhong, Zhao Lei, Shen JianJun, Xiao Qian, Liang ZhongFeng, Jiang ShuLian. Relationship between percentages of T lymphocytes in peripheral blood and deficiency of vital qi in patients with HBV- ACLF[J]. Journal of Clinical Hepatology, 2014, 30(4): 320-323. doi: 10.3969/j.issn.1001-5256.2014.04.009
[17]	Zhao DanTong, Yan HuiPing, Liao HuiYu, Liu YanMin, Feng Xia, Zhao Yan, Liu XiuHong, Kong XiangSha. Expression of Toll like receptors on peripheral blood mononuclear cells and their influence on CD4+CD25+T regula- tory cells in patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(1): 58-62.
[18]	Lu XiaoJu, Chen YongPing, Yang Tao, Cheng Yuan, Jin XiaoZhi, Shen ChunYan, Liu Jun, Wang ChunYing, Wang XiaoDong, Lin Zhuo. The influence of regulatory T cells in hepatic stellate cell proliferation and HA secretion[J]. Journal of Clinical Hepatology, 2012, 28(1): 39-43.
[19]	Li Li, Chen Ming, Pan XiuCheng, Wang LiPing, Fu JuanJuan, Feng Xia. Correlation between the recent thymic output function and the frequency of nave T cell in CHB patients[J]. Journal of Clinical Hepatology, 2011, 27(2): 157-160.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	张雄乐，陈芬兰，林文. 甲泼尼龙联合抗病毒药物治疗对乙型肝炎早期肝衰竭患者肝功能及炎性因子的影响. 中国医药指南. 2023(34): 98-101 .
2.	吴刚，叶晓玲，张宇，石磬. 单免疫球蛋白-白介素1受体蛋白在慢性乙肝患者中的表达水平变化及临床意义研究. 罕少疾病杂志. 2023(12): 72-74 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2947) PDF downloads(475)

Developmental history of the extent of lymph node dissection in pancreatic cancer surgery

DOI: 10.3969/j.issn.1001-5256.2017.01.012